- Home
- LRE vs BLRX Comparison
LRE vs BLRX Comparison
Compare LRE & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- BLRX
- Stock Information
- Founded
- LRE 2001
- BLRX 2003
- Country
- LRE Japan
- BLRX Israel
- Employees
- LRE N/A
- BLRX N/A
- Industry
- LRE
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- BLRX Health Care
- Exchange
- LRE Nasdaq
- BLRX Nasdaq
- Market Cap
- LRE 17.6M
- BLRX 15.3M
- IPO Year
- LRE 2023
- BLRX 2011
- Fundamental
- Price
- LRE $1.74
- BLRX $4.45
- Analyst Decision
- LRE
- BLRX Strong Buy
- Analyst Count
- LRE 0
- BLRX 2
- Target Price
- LRE N/A
- BLRX $19.00
- AVG Volume (30 Days)
- LRE 25.4K
- BLRX 2.1M
- Earning Date
- LRE 07-30-2015
- BLRX 08-14-2025
- Dividend Yield
- LRE N/A
- BLRX N/A
- EPS Growth
- LRE N/A
- BLRX N/A
- EPS
- LRE 0.29
- BLRX N/A
- Revenue
- LRE $117,804,154.00
- BLRX $22,340,000.00
- Revenue This Year
- LRE N/A
- BLRX N/A
- Revenue Next Year
- LRE N/A
- BLRX N/A
- P/E Ratio
- LRE $6.38
- BLRX N/A
- Revenue Growth
- LRE 8.82
- BLRX 91.68
- 52 Week Low
- LRE $1.10
- BLRX $2.30
- 52 Week High
- LRE $2.60
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- LRE 63.60
- BLRX 50.17
- Support Level
- LRE $1.64
- BLRX $3.79
- Resistance Level
- LRE $1.83
- BLRX $4.62
- Average True Range (ATR)
- LRE 0.16
- BLRX 0.56
- MACD
- LRE -0.02
- BLRX -0.13
- Stochastic Oscillator
- LRE 40.86
- BLRX 21.79
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.